Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES: Recent evidence has shown no harm associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) in patients with coronavirus disease 2019 (COVID-19). We sought to further clarify the possible association between ACEI/ARB use and the risk of poor clinical outcomes of COVID-19. METHODS: From the completely enumerated COVID-19 cohort in Korea, we identified 1,290 patients with hypertension, of whom 682 had and 603 did not have records of ACEI/ARB use during the 30-day period before their COVID-19 diagnosis. Our primary endpoint comprised clinical outcomes, including all-cause mortality, use of mechanical ventilation, intensive care unit admission, and sepsis. We used inverse probability of treatment weighting (IPTW) to mitigate selection bias, and a Poisson regression model to estimate the relative risks (RRs) and 95% confidence intervals (CIs) for comparing outcomes between ACEI/ARB users and non-users. RESULTS: Compared to non-use, ACEI/ARB use was associated with lower clinical outcomes (IPTW-adjusted RR, 0.60; 95% CI, 0.42 to 0.85; p=0.005). For individual outcomes, ACEI/ARB use was not associated with all-cause mortality (IPTW-adjusted RR, 0.62; 95% CI, 0.35 to 1.09; p=0.097) or respiratory events (IPTW-adjusted RR, 0.99; 95% CI, 0.84 to 1.17; p=0.904). Subgroup analysis showed a trend toward a protective role of ACEIs and ARBs against overall outcomes in men (IPTW-adjusted RR, 0.84; 95% CI, 0.69 to 1.03; pinteraction=0.008) and patients with pre-existing respiratory disease (IPTW-adjusted RR, 0.74; 95% CI, 0.60 to 0.92; pinteraction=0.002). CONCLUSIONS: We present clinical evidence to support continuing ACE/ARB use in COVID-19 patients with hypertension based on the completely enumerated Korean cohort.
Abstract
OBJECTIVES: Recent evidence has shown no harm associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) in patients with coronavirus disease 2019 (COVID-19). We sought to further clarify the possible association between ACEI/ARB use and the risk of poor clinical outcomes of COVID-19. METHODS: From the completely enumerated COVID-19 cohort in Korea, we identified 1,290 patients with hypertension, of whom 682 had and 603 did not have records of ACEI/ARB use during the 30-day period before their COVID-19 diagnosis. Our primary endpoint comprised clinical outcomes, including all-cause mortality, use of mechanical ventilation, intensive care unit admission, and sepsis. We used inverse probability of treatment weighting (IPTW) to mitigate selection bias, and a Poisson regression model to estimate the relative risks (RRs) and 95% confidence intervals (CIs) for comparing outcomes between ACEI/ARB users and non-users. RESULTS: Compared to non-use, ACEI/ARB use was associated with lower clinical outcomes (IPTW-adjusted RR, 0.60; 95% CI, 0.42 to 0.85; p=0.005). For individual outcomes, ACEI/ARB use was not associated with all-cause mortality (IPTW-adjusted RR, 0.62; 95% CI, 0.35 to 1.09; p=0.097) or respiratory events (IPTW-adjusted RR, 0.99; 95% CI, 0.84 to 1.17; p=0.904). Subgroup analysis showed a trend toward a protective role of ACEIs and ARBs against overall outcomes in men (IPTW-adjusted RR, 0.84; 95% CI, 0.69 to 1.03; pinteraction=0.008) and patients with pre-existing respiratory disease (IPTW-adjusted RR, 0.74; 95% CI, 0.60 to 0.92; pinteraction=0.002). CONCLUSIONS: We present clinical evidence to support continuing ACE/ARB use in COVID-19 patients with hypertension based on the completely enumerated Korean cohort.
참고문헌 (26)
- "WHO coronavirus disease (COVID-19) dashboard"[URL]
- Zheng YY, "COVID-19 and the cardiovascular system", Nat Rev Cardiol, 17, pp.259~260 (2020)
- Ferrario CM, "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensinconverting enzyme 2", Circulation, 111, pp.2605~2610 (2005)
- Karram T, "Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure", Am J Physiol Heart Circ Physiol, 289, pp.H1351~H1358 (2005)
- Ishiyama Y, "Upregulation of angiotensin-converting enzyme 2after myocardial infarction by blockade of angiotensin II receptors", Hypertension, 43, pp.970~976 (2004)
- Rodrigues Prestes TR, "The anti-inflammatory potential of ACE2", angiotensin-(1-7), Curr Drug Targets, pp.2017, 18[DOI]
- Namsolleck P, "AT(2)receptor and tissue injury : therapeutic implications", Curr Hypertens Rep, 16, pp.416~ (2014)
- Aronson JK, "Drugs and the renin-angiotensin system in covid-19", BMJ, 369, pp.m1313~ (2020)
- Li J, "Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019(COVID-19)infection in Wuhan, China", JAMA Cardiol, 5, pp.825~830 (2020)
- Meng J, "Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19patients with hypertension", Emerg Microbes Infect, 9, pp.757~760 (2020)
- Mancia G, "Reninangiotensin-aldosterone system blockers and the risk of Covid-19", N Engl J Med, 382, pp.2431~2440 (2020)
- Reynolds HR, "Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19", N Engl J Med, 382, pp.2441~2448 (2020)
- Zhang P, "Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19", Circ Res, 126, pp.1671~1681 (2020)
- 김연용, "Level of Agreement and Factors Associated With Discrepancies Between Nationwide Medical History Questionnaires and Hospital Claims Data", 예방의학회지, 50(5), pp.294~302 (2017), 대한예방의학회
- "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance; 2020"[URL]
- Brookhart MA, "Propensity score methods for confounding control in nonexperimental research", Circ Cardiovasc Qual Outcomes, 6, pp.604~611 (2013)
- Walls AC, "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", Cell, 181, pp.281~292 (2020)
- Khan A, "A pilot clinical trial of recombinant human angiotensinconverting enzyme 2 in acute respiratory distress syndrome", Crit Care, 21, pp.234~ (2017)
- Kuba K, "A crucial role of angiotensin converting enzyme 2(ACE2)in SARS coronavirus-induced lung injury", Nat Med, 11, pp.875~879 (2005)
- Imai Y, "Angiotensinconverting enzyme 2 protects from severe acute lung failure", Nature, 436, pp.112~116 (2005)
- "Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers"[URL]
- "HFSA/ACC/AHA statement addresses concerns. Re: using RAAS antagonists in COVID-19;2020 Mar 17"[URL]
- Kim SH, "Prescribing patterns of antihypertensives for treatment-naïve patients in South Korea : from Korean NHISS claim data", Int J Hypertens, 2019, pp.4735876~ (2019)
- "Coronavirus disease-19, Republic of Korea"[URL]
- U, "S. Preventive Services Task Force. Screening for osteoporosis : U. S. preventive services task force recommendation statement", Ann Intern Med, 154, pp.356~364 (2011)
- Ray WA, "Evaluating medication effects outside of clinical trials : new-user designs", Am J Epidemiol, 158, pp.915~920 (2003)